Related Experiment Video

Updated: Feb 18, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Bad phosphorylation as a target of inhibition in oncology

Ngoc-Linh-Chi Bui1, Vijay Pandey2, Tao Zhu3

  • 1Cancer Science Institute of Singapore, National University of Singapore, Singapore.

Cancer Letters
|November 28, 2017
PubMed

Insights

The Bcl-2 agonist of cell death (BAD) protein

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • The Bcl-2 agonist of cell death (BAD) is a key regulator of apoptosis and has non-apoptotic roles in cancer.
  • BAD's function shifts between pro-apoptotic and pro-survival based on phosphorylation at specific serine residues (S75, S99, S118).
  • BAD expression and phosphorylation patterns are implicated in tumor initiation, progression, and patient outcomes.

Purpose of the Study:

  • To review the current evidence on BAD phosphorylation in human cancers.
  • To evaluate the therapeutic potential of targeting BAD phosphorylation in cancer treatment.

Main Methods:

  • Literature review of studies investigating BAD phosphorylation in cancer.
  • Analysis of the functional roles of BAD phosphorylation in various cancer types.
  • Assessment of the clinical relevance of BAD phosphorylation patterns.

Main Results:

  • BAD phosphorylation significantly impacts cancer development and progression.
  • Phosphorylation status of BAD influences tumor initiation, metastasis, and response to therapy.
  • Altered BAD phosphorylation is linked to prognosis and chemosensitivity across different cancers.

Conclusions:

  • BAD phosphorylation is a critical determinant of its dual role in cancer.
  • Targeting BAD phosphorylation presents a promising strategy for novel cancer therapies.
  • Further research into BAD phosphorylation modulation could improve cancer treatment outcomes.
Keywords:
ApoptosisBAD phosphorylationBcl-2 familykinase inhibitor

More Related Videos

Oligopeptide Competition Assay for Phosphorylation Site Determination09:16

Oligopeptide Competition Assay for Phosphorylation Site Determination

Published on: May 18, 2017

8.9K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

831

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.2K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.5K
Phosphorylation01:02

Phosphorylation

The addition or removal of phosphate groups from proteins is the most common chemical modification that regulates cellular processes. These modifications can affect the structure, activity, stability, and localization of proteins within cells as well as their interactions with other proteins.
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
54.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.7K